Device Malfunctions Reported In Beta-Cath PMA Submission Not Significant
This article was originally published in The Gray Sheet
Executive Summary
A number of "minor device malfunctions" reported in Novoste's Beta-Cath radiation system premarket approval application do not detract from the device's efficacy, members of FDA's Circulatory System Devices Panel agreed Sept. 11.
You may also be interested in...
Novoste Meeting With FDA On Beta-Cath Labeling Issues Week Of Oct. 23
Preparations for the U.S. launch of Novoste's Beta-Cath intracoronary radiation catheter system to treat in-stent restenosis are nearly complete, and the firm hopes to receive final FDA approval in time for the American Heart Association meeting in mid-November. The company reported receiving an "approvable" letter from the agency on Oct. 16.
Novoste Meeting With FDA On Beta-Cath Labeling Issues Week Of Oct. 23
Preparations for the U.S. launch of Novoste's Beta-Cath intracoronary radiation catheter system to treat in-stent restenosis are nearly complete, and the firm hopes to receive final FDA approval in time for the American Heart Association meeting in mid-November. The company reported receiving an "approvable" letter from the agency on Oct. 16.
Novoste, J&J Could Gain Simultaneous PMA Approvals For Brachy Systems
Novoste is anticipating FDA approval of its Beta-Cath beta radiation system for treatment of in-stent restenosis at the same time as Johnson & Johnson's Checkmate gamma system.